for the treatment of Disease
AngioSoma (OTCBB: SOAN) a Clinical Stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. Our team of executives and medical professionals understand the importance of solving the MS puzzle. With over 150 years of combined drug development and medical experience, we are confident in the initial data and the course we have charted.
In clinical trials, AngioSoma’s patented drug combination has shown an improvement in the symptoms and quality of life for Multiple Sclerosis patients. We are initiating discussions with the FDA on clinical trial design in preparation for our FDA submission and approval pathway in 2021.
In all, we have a robust product pipeline from 20+ years of research and development, with existing patents, provisional patents, formulations, and trademarks from previously successful products.